CLVS.O
Latest Trade
6.68USDChange
0.00(0.00%)Volume
998Today's Range
-
--52 Week Range
-
11.63As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 6.68 |
|---|---|
Open | 0.00 |
Volume | 998 |
3M AVG Volume | 106.06 |
Today's High | -- |
Today's Low | -- |
52 Week High | 11.63 |
52 Week Low | 3.62 |
Shares Out (MIL) | 88.32 |
Market Cap (MIL) | 589.97 |
Forward P/E | -1.67 |
Dividend (Yield %) | -- |
Clovis Oncology Announces Preliminary Product Revenues For Q4 And Full Year 2020
Clovis Oncology's Rubraca Met The Primary Endpoint In Phase 3 Treatment Study In Later-Line Ovarian Cancer Patients With A Brca Mutation
Clovis Oncology Reports Q3 Loss Per Share $0.89
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
Industry
Biotechnology & Drugs
Contact Info
5500 Flatiron Pkwy Unit 100
BOULDER, CO
80301-2834
United States
+1.303.6255000
http://clovisoncology.comExecutive Leadership
Ginger L. Graham
Independent Chairman of the Board
Patrick J. Mahaffy
President, Chief Executive Officer, Co-Founder, Director
Gillian C. Ivers-Read
Co-Founder, Executive Vice President, Chief Regulatory Officer
Daniel W. Muehl
Chief Financial Officer, Executive Vice President
Paul E. Gross
Executive Vice President, General Counsel
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 3.68 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -68.82 |
Return on Equity (TTM) | -56.45 |
* CLOVIS ONCOLOGY TO HIGHLIGHT RUBRACA® (RUCAPARIB) AND LUCITANIB NON-CLINICAL DATA AT THE AACR VIRTUAL ANNUAL MEETING II 2020 Source text for Eikon: Further company coverage:
* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER
* CLOVIS ONCOLOGY - ANNOUNCES NEW RECOMMENDATIONS FOR RUBRACA FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:
* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
* CLOVIS ONCOLOGY ANNOUNCES PROPOSED OFFERING OF COMMON STOCK
* CLOVIS ONCOLOGY - PRICE FOR RUBRACA IN PROSTATE CANCER WILL ALIGN TO PRICING FOR OVARIAN CANCER INDICATIONS
Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug's use in patients whose...
* RUBRACA® (RUCAPARIB) APPROVED IN THE U.S. AS MONOTHERAPY TREATMENT FOR PATIENTS WITH BRCA1/2-MUTANT, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2020 OPERATING RESULTS
* CLOVIS ONCOLOGY SAYS CEO PATRICK J. MAHAFFY'S 2019 TOTAL COMPENSATION WAS $6.9 MILLION VERSUS $6.3 MILLION IN 2018 – SEC FILING
* CLOVIS ONCOLOGY ANNOUNCES DEBT EXCHANGE TRANSACTION Source text for Eikon: Further company coverage:
* Q4 EARNINGS PER SHARE ESTIMATE $-1.71 -- REFINITIV IBES DATA
Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.
U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.
* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS
* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:
* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK
* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $200 MILLION PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025 - SEC FILING Source text: (https://bit.ly/2qzin28) Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2HCYkbd) Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.